TY - JOUR
T1 - Anakinra drug retention rate and predictive factors of long-term response in systemic juvenile idiopathic arthritis and adult onset still disease
AU - Sota, Jurgen
AU - Rigante, Donato
AU - Ruscitti, Piero
AU - Insalaco, Antonella
AU - Sfriso, Paolo
AU - De Vita, Salvatore
AU - Cimaz, Rolando
AU - Lopalco, Giuseppe
AU - Emmi, Giacomo
AU - Torre, Francesco La
AU - Fabiani, Claudia
AU - Olivieri, Alma Nunzia
AU - Cattalini, Marco
AU - Cammelli, Daniele
AU - Gallizzi, Romina
AU - Alessio, Maria
AU - Manna, Raffaele
AU - Viapiana, Ombretta
AU - Frassi, Micol
AU - Pardeo, Manuela
AU - Maier, Armin
AU - Salvarani, Carlo
AU - Talarico, Rosaria
AU - Mosca, Marta
AU - Colafrancesco, Serena
AU - Priori, Roberta
AU - Maggio, Maria Cristina
AU - Gaggiano, Carla
AU - Grosso, Salvatore
AU - De Benedetti, Fabrizio
AU - Vitale, Antonio
AU - Giacomelli, Roberto
AU - Cantarini, Luca
PY - 2019/1/1
Y1 - 2019/1/1
N2 - Background and objective: Only a few studies have reported long-term efficacy of interleukin (IL)-1 inhibition in systemic juvenile idiopathic arthritis (sJIA) and adult onset Still disease (AOSD). Herein we report on the effectiveness of Anakinra (ANA), expressed in terms of drug retention rate (DRR), and evaluate the predictive factors of drug survival in a cohort of patients with sJIA and AOSD. Patients and methods: This is a multicentre study reviewing retrospectively the medical records from 61 patients with sJIA and 76 with AOSD, all treated with ANA in 25 Italian tertiary referral centers. Results: The cumulative retention rate of ANA at 12-, 24-, 48- and 60-months of follow-up was 74.3%, 62.9%, 49.4% and 49.4%, respectively, though without any significant differences between sJIA and AOSD patients (p=0.164), and between patients treated in monotherapy compared with the subgroup co-administered with conventional disease modifying anti-rheumatic drugs (cDMARDs) (p=0.473). On the other hand, a significant difference in DRR was found between biologic-naïve patients and those previously treated with biotechnologic drugs (p=0.009), which persisted even after adjustment for pathology (p=0.013). In the regression analysis, patients experiencing adverse events (AEs) (HR=3.029 [C.I. 1.750-5.242], p
AB - Background and objective: Only a few studies have reported long-term efficacy of interleukin (IL)-1 inhibition in systemic juvenile idiopathic arthritis (sJIA) and adult onset Still disease (AOSD). Herein we report on the effectiveness of Anakinra (ANA), expressed in terms of drug retention rate (DRR), and evaluate the predictive factors of drug survival in a cohort of patients with sJIA and AOSD. Patients and methods: This is a multicentre study reviewing retrospectively the medical records from 61 patients with sJIA and 76 with AOSD, all treated with ANA in 25 Italian tertiary referral centers. Results: The cumulative retention rate of ANA at 12-, 24-, 48- and 60-months of follow-up was 74.3%, 62.9%, 49.4% and 49.4%, respectively, though without any significant differences between sJIA and AOSD patients (p=0.164), and between patients treated in monotherapy compared with the subgroup co-administered with conventional disease modifying anti-rheumatic drugs (cDMARDs) (p=0.473). On the other hand, a significant difference in DRR was found between biologic-naïve patients and those previously treated with biotechnologic drugs (p=0.009), which persisted even after adjustment for pathology (p=0.013). In the regression analysis, patients experiencing adverse events (AEs) (HR=3.029 [C.I. 1.750-5.242], p
KW - Adult onset Still disease
KW - Anakinra
KW - Drug retention rate
KW - Innovative biotechnologies
KW - Interleukin 1-beta
KW - Personalized medicine
KW - Systemic juvenile idiopathic arthritis
U2 - 10.3389/fphar.2019.00918
DO - 10.3389/fphar.2019.00918
M3 - Article
VL - 10
JO - Front. Pharmacol.
JF - Front. Pharmacol.
SN - 1663-9812
IS - JULY
ER -